Screening for Fabry disease in patients with left ventricular noncompaction.


Journal

Revista portuguesa de cardiologia
ISSN: 2174-2049
Titre abrégé: Rev Port Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101770878

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 23 09 2018
accepted: 03 02 2019
pubmed: 7 1 2020
medline: 25 8 2020
entrez: 6 1 2020
Statut: ppublish

Résumé

It is unclear whether left ventricular noncompaction (LVNC) is a distinct cardiomyopathy or a morphologic manifestation of different cardiomyopathies. We previously reported a case of LVNC in a Fabry disease (FD) patient, but it remains to be clarified whether LVNC is a cardiac manifestation of FD, a coincidental finding or an overdiagnosis, which has major therapeutic implications. This study aims to determine the prevalence of FD among patients with LVNC. We performed a retrospective study including all patients diagnosed with LVNC in eight hospital centers. Diagnosis of LVNC was based on at least one echocardiographic or cardiac magnetic resonance criterion. FD screening was performed by combined enzyme and genetic testing. The study included 78 patients diagnosed with LVNC based on the Jenni (84.6%), Stöllberger (46.2%), Chin (21.8%), Petersen (83.8%) and Jacquier (16.2%) criteria. Left ventricular systolic dysfunction was present in 48.7%. Heart failure was found in 60.3%, ventricular dysrhythmias in 21.6% and embolic events in 11.5%. FD screening found no additional cases among patients with LVNC, besides the previously described case. No additional FD cases were found among patients with LVNC, which argues against the hypothesis that LVNC is a cardiac manifestation of FD.

Identifiants

pubmed: 31901299
pii: S0870-2551(19)30569-4
doi: 10.1016/j.repc.2019.02.014
pii:
doi:

Types de publication

Journal Article

Langues

eng por

Sous-ensembles de citation

IM

Pagination

709-716

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Olga Azevedo (O)

Cardiology Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal. Electronic address: olgazevedo@yahoo.com.br.

Nuno Marques (N)

Cardiology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal; Algarve Biomedical Center, Faro, Portugal; Biomedical Science and Medicine Department, Algarve University, Faro, Portugal.

Nuno Craveiro (N)

Cardiology Department, Hospital de Santarém, Santarém, Portugal.

Ana Rita Pereira (AR)

Cardiology Department, Hospital Garcia de Orta, Almada, Portugal.

Hugo Antunes (H)

Cardiology Department, Centro Hospitalar de Tondela e Viseu, Viseu, Portugal.

Liliana Reis (L)

Cardiology Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.

Rui Azevedo Guerreiro (RA)

Cardiology Department, Hospital do Espírito Santo, Évora, Portugal.

Rui Pontes Dos Santos (R)

Cardiology Department, Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal.

Gabriel Miltenberger-Miltenyi (G)

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal; Genetics Department, Reference Center on Lysosomal Storage Disorders, Hospital Senhora da Oliveira, Guimarães, Portugal.

Nuno Sousa (N)

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Damião Cunha (D)

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; ICVS/3Bs PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH